SALT LAKE CITY, March 13, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCPINK:PRED), a
life-sciences technology company, today announces new clinical data relating to the role of genetics in the development of
endometriosis. These data were featured in three presentations by its development partner Juneau Biosciences, LLC at the
Society for Reproductive Investigation’s (SRI) 65th Annual Scientific Meeting. The meeting was
held March 5-10, 2018 in San Diego. Predictive Technology Group’s wholly owned subsidiary Predictive Therapeutics is developing novel therapeutics and proprietary gene-based non-invasive
diagnostics for endometriosis.
Highlights of the presentations are as follows:
- “Rare Synonymous Mutations Show Strong Association with Endometriosis.” Juneau Biosciences’ Chief Science Officer
Hans Albertsen, Ph.D., in an oral presentation, presented an analysis of 1,077 study participants with surgically diagnosed
endometriosis, indicating that low-frequency DNA variants may play a role in the genetic predisposition of this disease even when
they do not change the amino acid building blocks for the encoded protein.
- “A Family with over 200 Women with Confirmed Endometriosis Suggesting Autosomal Dominant Influence.” Juneau
Biosciences’ CEO Kenneth Ward, M.D. presented a poster highlighting the study of familial endometriosis using a unique genealogy
database of 32 million ancestors of the present population of the western U.S. The study shows a high incidence of
surgically proven endometriosis in the recent generations of a single family with endometriosis spanning 19 generations. Millions
of women may carry the risk factor described in this study.
- “Large Effect Mutations Found in Endometriosis Genes Implicated by GWAS.” Dr. Ward also presented data
providing the first comprehensive study of mutations in genes implicated by previous genome-wide associated studies (GWAS).
The identified mutations are strong risk factors for developing endometriosis, distinct from the much weaker signals observed in
GWAS. The discovery of mutations having large effects confirm a critical role for these genes in the pathogenesis of
endometriosis.
“We understand that endometriosis runs in families, and the precise genetic mechanisms behind this disorder are now coming into
focus,” said Dr. Ward. “Results from Juneau’s studies are being assembled into genetic tests to more accurately diagnosis
women with endometriosis symptoms, as well as predicting disease in women at high risk for developing this disorder.”
“Each of these studies addresses the tremendous value of research in the role genetics play in endometriosis,” said Bradley
Robinson, President and CEO of Predictive Technology Group. “We look forward to incorporating these valuable insights into the
development of genetically based test and targeted therapies that can be employed at a much earlier stage to help mitigate the
effects of this disorder.”
About the Society for Reproductive Investigation’s (SRI) Annual Meeting
The SRI annual scientific meeting gathers leading scientists and clinical investigators to share cutting-edge information in
reproductive sciences and women’s health. The 65th Annual Meeting featured an exciting lineup of distinguished
lecturers, 12 mini-symposia sessions, several new investigator events, career development sessions, and scientific oral and poster
presentations. More information is available at http://www.sri-online.org/.
About Predictive Technology Group, Inc.
Predictive Technology Group , Inc. aims to revolutionize patient care through predictive data analytics, novel gene-based
diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These
subsidiaries are focuses on endometriosis, scoliosis, degenerative disc disease and regenerative tissue products. The subsidiaries
use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and
therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is at
www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development
and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property
rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to
time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/903e3907-ff0d-4294-9209-3c2b044b5fce
